BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 14718597)

  • 1. Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption.
    Onyia JE; Galvin RJ; Ma YL; Halladay DL; Miles RR; Yang X; Fuson T; Cain RL; Zeng QQ; Chandrasekhar S; Emkey R; Xu Y; Thirunavukkarasu K; Bryant HU; Martin TJ
    J Pharmacol Exp Ther; 2004 Apr; 309(1):369-79. PubMed ID: 14718597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice.
    Schett G; Redlich K; Hayer S; Zwerina J; Bolon B; Dunstan C; Görtz B; Schulz A; Bergmeister H; Kollias G; Steiner G; Smolen JS
    Arthritis Rheum; 2003 Jul; 48(7):2042-51. PubMed ID: 12847699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice.
    Tabuchi M; Miyazawa K; Kimura M; Maeda H; Kawai T; Kameyama Y; Goto S
    Calcif Tissue Int; 2005 Oct; 77(4):239-49. PubMed ID: 16193235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures.
    Kaji H; Kanatani M; Sugimoto T; Chihara K
    Horm Metab Res; 2005 Oct; 37(10):589-92. PubMed ID: 16278780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
    Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
    Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism.
    Padagas J; Colloton M; Shalhoub V; Kostenuik P; Morony S; Munyakazi L; Guo M; Gianneschi D; Shatzen E; Geng Z; Tan HL; Dunstan C; Lacey D; Martin D
    Calcif Tissue Int; 2006 Jan; 78(1):35-44. PubMed ID: 16362459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice.
    Kostenuik PJ; Bolon B; Morony S; Daris M; Geng Z; Carter C; Sheng J
    Bone; 2004 Apr; 34(4):656-64. PubMed ID: 15050896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene.
    Onyia JE; Miles RR; Yang X; Halladay DL; Hale J; Glasebrook A; McClure D; Seno G; Churgay L; Chandrasekhar S; Martin TJ
    J Bone Miner Res; 2000 May; 15(5):863-71. PubMed ID: 10804015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.
    Fisher JL; Thomas-Mudge RJ; Elliott J; Hards DK; Sims NA; Slavin J; Martin TJ; Gillespie MT
    Cancer Res; 2006 Apr; 66(7):3620-8. PubMed ID: 16585187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha.
    Wada N; Maeda H; Yoshimine Y; Akamine A
    Bone; 2004 Sep; 35(3):629-35. PubMed ID: 15336598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoprotegerin in prostate cancer bone metastasis.
    Corey E; Brown LG; Kiefer JA; Quinn JE; Pitts TE; Blair JM; Vessella RL
    Cancer Res; 2005 Mar; 65(5):1710-8. PubMed ID: 15753366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteocalcin fragment in bone matrix enhances osteoclast maturation at a late stage of osteoclast differentiation.
    Ishida M; Amano S
    J Bone Miner Metab; 2004; 22(5):415-29. PubMed ID: 15316862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adeno-associated virus-mediated osteoprotegerin gene transfer protects against particulate polyethylene-induced osteolysis in a murine model.
    Yang SY; Mayton L; Wu B; Goater JJ; Schwarz EM; Wooley PH
    Arthritis Rheum; 2002 Sep; 46(9):2514-23. PubMed ID: 12355500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triiodothyronine (T3) and 1,25-dihydroxyvitamin D3 (1,25D3) inversely regulate OPG gene expression in dependence of the osteoblastic phenotype.
    Varga F; Spitzer S; Klaushofer K
    Calcif Tissue Int; 2004 Apr; 74(4):382-7. PubMed ID: 15255076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells.
    Humphrey EL; Williams JH; Davie MW; Marshall MJ
    Bone; 2006 May; 38(5):652-61. PubMed ID: 16298558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy.
    Capparelli C; Kostenuik PJ; Morony S; Starnes C; Weimann B; Van G; Scully S; Qi M; Lacey DL; Dunstan CR
    Cancer Res; 2000 Feb; 60(4):783-7. PubMed ID: 10706080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity.
    Lossdörfer S; Schwartz Z; Wang L; Lohmann CH; Turner JD; Wieland M; Cochran DL; Boyan BD
    J Biomed Mater Res A; 2004 Sep; 70(3):361-9. PubMed ID: 15293309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of secretion of osteoprotegerin in rat dental follicle cells.
    Wise GE; Ding D; Yao S
    Eur J Oral Sci; 2004 Oct; 112(5):439-44. PubMed ID: 15458504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.
    Kanatani M; Sugimoto T; Sowa H; Kobayashi T; Kanzawa M; Chihara K
    J Cell Physiol; 2004 Oct; 201(1):17-25. PubMed ID: 15281085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.
    Morony S; Capparelli C; Sarosi I; Lacey DL; Dunstan CR; Kostenuik PJ
    Cancer Res; 2001 Jun; 61(11):4432-6. PubMed ID: 11389072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.